Zenlabs Ethica Limited reported impressive Q1 FY2026 results. Revenue increased by 21.9% to ₹957.50 crore. EBITDA grew by 29.4% to ₹212.98 crore, with margin expanding to 22.2%. Profit After Tax surged by 50.9% to ₹131.90 crore. The company launched three new products, filed two ANDAs with USFDA, received approval for one generic product, and commenced production at a new facility. Zenlabs maintains a strong financial position with net cash of ₹205.98 crore.
Zenlabs Ethica Limited reported a 20.33% decrease in net profit for Q1, falling to ₹3.33 crore from ₹4.18 crore year-over-year. Revenue from operations declined by 7.16% to ₹1,147.72 crore. The company's Board approved new insider trading policies to enhance corporate governance, including codes for fair disclosure of unpublished price sensitive information and regulating insider trading.